CAH

Cardinal Health Inc. 10-Q Summary: Quarter Ended September 30, 2004

Business Context and Reporting Period

This Form 10-Q covers the three-month period ended September 30, 2004 (First Quarter of Fiscal 2005). Cardinal Health, Inc. is a diversified health care services company operating through four segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services, Pharmaceutical Technologies and Services, and Clinical Technologies and Services. The reporting period is significantly impacted by an ongoing SEC formal investigation, a U.S. Attorney inquiry, and an internal Audit Committee review regarding accounting practices, leading to restatements of prior financial periods.

Key Financial Metrics

Note: Total Debt calculated as Notes payable ($4.2M) + Current portion of long-term obligations ($358.2M) + Long-term obligations ($2,892.6M).

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 16% year-over-year, driven by higher sales volume across all segments, new customer contracts, and the acquisition of ALARIS Medical Systems (included in Clinical Technologies and Services).
• Profitability Decline: Operating earnings decreased 29% and Net Earnings decreased 25%. This decline is attributed to:
• Special items totaling $31.9 million (vs. $13.2 million prior year), including $16.9 million in merger-related costs and $7.5 million in restructuring costs.
• A $16.4 million charge for latex litigation liabilities.
• Reduced vendor margins in the Pharmaceutical Distribution segment due to changes in manufacturer pricing and sales practices.
• Increased competition and softening demand in the Pyxis products business.
• Cash Flow Improvement: Operating cash flow surged to $893.2 million (up $599.1 million) primarily due to a $1,247.7 million increase in accounts payable and a $76.3 million decrease in trade receivables (partially due to selling $500 million in receivables).
• Accounting Restatements: The company restated financial statements for fiscal years 2000-2003 and the first three quarters of 2004 due to errors in revenue recognition (premature execution of equipment confirmations), cash discount recognition, and balance sheet reserve adjustments.

Guidance, Outlook, and Risks

• Restructuring ("Operation One Cardinal Health"): The company announced a company-wide restructuring program targeting $125 million in cost savings for fiscal 2005. Initial costs of $2.5 million were incurred in this quarter.
• Pharmaceutical Distribution Transition: Management is actively working to transition the compensation model for pharmaceutical distribution from volume-based incentives to a fee-for-service model to address reduced margins caused by manufacturer pricing changes. A deadline of April 1, 2005, was set for agreements.
• Legal and Regulatory Risks:
  • SEC/U.S. Attorney Investigation: Ongoing formal investigations into revenue classification and accounting practices. The outcome could result in fines, penalties, or further restatements.
  • Internal Controls: Management and auditors identified "material weaknesses" in internal controls regarding revenue recognition and the control environment. Disclosure controls were deemed not effective as of September 30, 2004.
  • Litigation: Significant pending litigation includes shareholder derivative suits, ERISA actions, and latex glove injury claims (partially settled with a $16.4M charge).
• Liquidity: The company maintains $1.5 billion in revolving credit facilities. Subsequent to the quarter-end, the company borrowed and repaid significant amounts to fund inventory for a new National Logistics Center.

Investor Verification Checklist

• Restatement Impact: Verify the specific dollar impact of the restatements on prior year comparables and the extent of the "cumulative effect of change in accounting" ($38.5 million reduction in prior year net earnings).
• Internal Control Remediation: Review the specific steps being taken to address the material weaknesses in revenue recognition and the timeline for achieving effective controls.
• Pharmaceutical Margin Recovery: Assess the progress of negotiations with pharmaceutical manufacturers for the new fee-for-service compensation model and the risk of failing to secure adequate margins.
• Special Items Recurrence: Determine if the $31.9 million in special items (merger, restructuring, litigation) represents a one-time cost or the beginning of a sustained period of elevated expenses.
• Pyxis Segment Performance: Monitor the trend in the Pyxis products business, which faced a 7% revenue decline and margin pressure, to see if the "softening demand" is temporary or structural.